The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.
Age range
18 Years – 55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately 113 Days
Maximum Observed Concentration (Cmax) of ABBV-8736
Timeframe: Up to Approximately 113 Days
Time to Cmax (Tmax) of ABBV-8736
Timeframe: Up to Approximately 113 Days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of ABBV-8736
Timeframe: Up to Approximately 113 Days
Observed plasma concentration at the end of a dosing interval (Ctrough) of ABBV-8736
Timeframe: Up to Approximately 113 Days
Apparent Terminal Phase Elimination Rate Constant (β) of ABBV-8736
Timeframe: Up to Approximately 113 Days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-8736
Timeframe: Up to Approximately 113 Days
Clearance (CL) for Intravenous (IV) Dosing
Timeframe: Up to Approximately 113 Days
Immunogenicity of ABBV-8736 as Determined by Anti-Drug Antibodies (ADAs)
Timeframe: Up to Approximately 113 Days